Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: belantamab mafodotin Clear all
Active, not recruiting Phase 2 Interventional

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

NCT04876248
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Lenalidomide
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 2 Interventional

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

NCT05208307
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03848845
View directory record Official record
Conditions
Multiple Myeloma
Interventions
belantamab mafodotin, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 27, 2026, 1:58 PM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

NCT02064387
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GSK2857916
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 27, 2026, 1:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Tucson, Arizona • Pueblo, Colorado • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Completed Phase 1Phase 2 Interventional

Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

NCT05493618
View directory record Official record
Conditions
Multiple Myeloma, Refractory
Interventions
Pembrolizumab, Belantamab mafodotin, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 27, 2026, 1:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

NCT03525678
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Not yet recruiting Phase 2 Interventional

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

NCT05874193
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
Cristiana Costa Chase, DO
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Clayton, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

NCT05055063
View directory record Official record
Conditions
Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
5
States / cities
Yuma, Arizona • Denver, Colorado • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT05091372
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Belantamab mafodotin, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

NCT05556798
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab Mafodotin, Nirogacestat, Pomalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Completed No phase listed Observational Results available

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05986682
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Blenrep
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Timeline
2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT04896658
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Terminated Phase 1 Interventional

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

NCT04892264
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT05145816
View directory record Official record
Conditions
AL Amyloidosis, Amyloidosis
Interventions
Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks), Belantamab mafodotin 1.9 mg/kg (12 weeks), Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages, Belantamab mafodotin 1.0 mg/kg (12 weeks)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Nashville, Tennessee • Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

NCT04643002
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 27, 2026, 1:58 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672
View directory record Official record
Conditions
Amyloidosis
Interventions
Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 27, 2026, 1:58 PM EDT